Barclays initiated coverage of Progyny with an Outperform rating and $48 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PGNY:
- Progyny management to meet with BTIG
- Progyny price target lowered to $49 from $57 at JPMorgan
- Progyny, Inc. to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Progyny price target lowered to $45 from $50 at KeyBanc
- Progyny sees FY23 revenue $1.087B-$1.1B, consensus 1.08B